| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780071 | Gynecologic Oncology | 2018 | 5 Pages |
Abstract
Cabozantinib demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Panagiotis A. Konstantinopoulos, William E. Brady, John Farley, Amy Armstrong, Denise S. Uyar, David M. Gershenson,